Patients with a faulty heartbeat want Pradaxa - and their clinicians want them to have it, too. You can understand why - when the UK authorities licensed the drug for treating atrial fibrillation in ...
The safety of Boehringer Ingelheim’s anticoagulant Pradaxa has been placed under the spotlight once again by a British Medical Journal (BMJ) probe. The journal claims Pradaxa (dabigatran) can lead to ...
NEW YORK, NY (updated) — Legal documents unsealed this week in court reveal that employees at Boehringer Ingelheim were so concerned about a research paper suggesting patients taking dabigatran ...
The sometimes-fatal bleeding risk of Pradaxa, the popular anticoagulant and alternative to warfarin, has been a concern to the FDA since the drug was approved in 2010. FDA and clinical reviews have ...
Editor's Note: This post originally appeared at drjohnm.org. Before addressing the article's mistakes, it is laudable that mainstream media emphasizes the notion of weighing risks. All medical ...
ST. PAUL, Minn., Oct. 20, 2011 /PRNewswire/ -- Treating patients with the new blood thinning medication dabigatran (Pradaxa®), instead of warfarin results in significantly higher per patient costs and ...
Forbes contributors publish independent expert analyses and insights. I'm a medical journalist covering cardiology news. All the new oral anticoagulants are trying to displace warfarin, the ...
Reports from Ireland and New Zealand may herald new concerns about the Riata defibrillator leads (St. Jude Medical) and dabigatran (Pradaxa). A poster presented at the European Society of Cardiology ...
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of dabigatran etexilate, having considered evidence on the nature of deep vein thrombosis (DVT) and pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback